I want to quickly correct the record from the testimony we heard. The problem that Apotex faced, as well as the NGOs, was identifying the country up front. That process took a year or more. That was the real problem.
The way that CAMR is built requires certain elements that create the barriers from the operational standpoint to be triggered later on, once those things are completed, so this is what this is about. It's to fix that critical fatal flaw of process that will allow the medicines to be negotiated from the countries, the NGOs. From Mr. Abbott's testimony, we do know that this is WTO compliant.